A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
نویسندگان
چکیده
منابع مشابه
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase. Sequential inhibition of ribonucleotide reductase with triapine and an M1 ribonucleotide reductase inhibitor ...
متن کاملInhibition of ribonucleotide reductase activity by IC202C.
suppresses DNAsynthesis by inhibition of ribonucleotide reductase.4) Ribonucleotide reductase plays an essential role in DNAsynthesis in most organisms.5) The enzyme is a nonheme iron-containing protein, which requires ATPand Mg2+ as co factors. As previously reported that IC202C has art affinity against Fe(III) ion,3) we have examined the effect of IC202C on ribonucleotide reductase activity u...
متن کاملJAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to suppress the cytokine signalling cascade caused by the constitutive activation of JAK2. In clinical trials, JAK2 inhibitors are efficient in decreas...
متن کاملJAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.
Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have been reported in ruxolitinib-treated patients, and natural killer (NK) cells are immune effector cells known to eliminat...
متن کاملEpigenetics in Myeloproliferative Neoplasms
A decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mechanisms. Epigenetic changes are not due to a change in the DNA sequence but are reversible modifications that dictate the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2013
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.2013.097246